BIOVIE INC.
About BIOVIE INC.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2016
- $0
- Net income
- -$17.5M
- Total assets
- $21.6M
- Market cap
- $12.1M
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $18.1M
- Operating income
- -$18.1M
- Net income
- -$17.5M
- EPS (basic)
- $-12.12
- EPS (diluted)
- $-12.12
Balance sheet
- Total assets
- $21.6M
- Current assets
- $20.7M
- Total liabilities
- $2.6M
- Current liabilities
- $2.3M
- Shareholders’ equity
- $19.0M
Cash flow
- Operating cash flow
- -$19.0M
- Investing cash flow
- $6.3M
- Financing cash flow
- $12.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.1M
- EPS (diluted)
- $-12.12
- Shares outstanding
- 7.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 14, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.5M in FY2016.
- Trading 86% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIOVIE INC..
Write a review
News about BIOVIE INC.
News & sentiment via Polygon.io
